ALCHEMAB THERAPEUTICS
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.
ALCHEMAB THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2019-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.alchemab.com
Total Employee:
11+
Status:
Active
Total Funding:
85.59 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Global Site Tag Google Analytics 4 Nginx
Similar Organizations
Acesion Pharma
Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation.
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Aristea Therapeutics
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
Avea Life
Science-Based Longevity supplements formulated in Switzerland to help you be as young as you feel.
Calypso Biotech
Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Ucello Therapeutics
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Current Advisors List
Board_member
2019-01-01
Current Employees Featured
Uri Laserson Scientific Founder @ Alchemab Therapeutics
Scientific Founder
2019-10-01
Jane Osbourn Co-Founder, Chief Scientific Officer & Chief Technology Officer @ Alchemab Therapeutics
Co-Founder, Chief Scientific Officer & Chief Technology Officer
2019-01-01
OLIVIA CAVLAN Head of Business & Operations @ Alchemab Therapeutics
Head of Business & Operations
Rachael Bashford-Rogers Co-Founder @ Alchemab Therapeutics
Co-Founder
2019-01-01
GAVIN KILPATRICK Head of Neuroscience and Academic Liaison @ Alchemab Therapeutics
Head of Neuroscience and Academic Liaison
Ben Larman Co-Founder @ Alchemab Therapeutics
Co-Founder
Young T Kwon CEO @ Alchemab Therapeutics
CEO
2022-05-01
Founder
Investors List
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Alchemab Therapeutics
Biomedical Catalyst Fund
Biomedical Catalyst Fund investment in Grant - Alchemab Therapeutics
RA Capital Management
RA Capital Management investment in Series A - Alchemab Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Series A - Alchemab Therapeutics
DCVC
DCVC investment in Series A - Alchemab Therapeutics
Dementia Discovery Fund
Dementia Discovery Fund investment in Series A - Alchemab Therapeutics
SV Health Investors
SV Health Investors investment in Series A - Alchemab Therapeutics
DHVC
DHVC investment in Series A - Alchemab Therapeutics
DCVC Bio
DCVC Bio investment in Seed Round - Alchemab Therapeutics
Dementia Discovery Fund
Dementia Discovery Fund investment in Seed Round - Alchemab Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-26 | Alchemab Appoints Young T. Kwon as Chief Executive Officer |
| 2021-11-15 | Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and Operating Officer |
Official Site Inspections
http://www.alchemab.com Semrush global rank: 6.21 M Semrush visits lastest month: 1.09 K
- Host name: 139.254.197.35.bc.googleusercontent.com
- IP address: 35.197.254.139
- Location:
- Latitude: 47
- Longitude: 8
- Timezone: Europe/Vaduz
More informations about "Alchemab Therapeutics"
Reverse engineering human nature | Alchemab Therapeutics
Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology. The highly specialized patient …See details»
Executive Leadership | Groups | Alchemab Therapeutics
Jane Osbourn is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, …See details»
Alchemab Therapeutics - Crunchbase Company Profile …
Additionally, Alchemab Therapeutics has successfully raised an $82 million funding round, providing significant financial resources to support its …See details»
Alchemab Therapeutics - Leadership Team - The Org
The Leadership Team at Alchemab Therapeutics is responsible for guiding the strategic direction and vision of the company, ensuring the successful integration of innovative drug discovery …See details»
Member profile: Alchemab Therapeutics | BIA - BioIndustry
Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology. The highly specialized patient …See details»
Alchemab Therapeutics - VentureRadar
Alchemab identifies these naturally occurring protective antibodies by mining the antibody repertoires of individuals who are resistant to or recovered from disease. We are developing …See details»
Eli Lilly signs $415m deal for Alchemab’s ALS therapy
6 days ago ATLX-1282 is the lead asset from Alchemab’s proprietary discovery platform, which identifies antibodies associated with resilience to disease by analysing immune responses in genetically at-risk but asymptomatic …See details»
Alchemab Therapeutics - MassBio
Jul 31, 2023 Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery …See details»
Alchemab Therapeutics - Craft
Alchemab Therapeutics is a biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies. The company has developed a …See details»
Eli Lilly licenses early-stage ALS drug program from Alchemab in …
6 days ago This is the first drug licensed from the January 2025 collaboration pact between the two companies, which focused on ALS research. Under the terms of that deal, Alchemab and …See details»
Alchemab Therapeutics signs landmark $415m licensing …
6 days ago Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With …See details»
Alchemab, Inc. Company Profile | Waltham, MA - Dun & Bradstreet
Added by Alchemab, Inc. This information is updated and provided by Alchemab, Inc. The content available on the D&B Business Directory is provided "as-is" and "as-available" and may not be …See details»
Lilly forges a $415m ALS alliance with UK biotech Alchemab
6 days ago Alchemab's chief executive, Jane Osbourn, said the Lilly deal is a "landmark transaction" for the company, adding: "With Lilly's deep expertise in neurological conditions, …See details»
Alchemab Therapeutics Ltd Company Profile: Funding, Investors ...
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.Alchemab’s engine is …See details»
Senior Leadership | Groups | Alchemab Therapeutics
Jenny Howell oversees project management at Alchemab and is responsible for managing our research and development portfolio and projects. Prior to joining Alchemab, Jenny held …See details»
Join Our Team! | Alchemab Therapeutics
Careers. We are dedicated to the discovery and development of therapeutics to treat and cure neurodegenerative diseases and cancer, and we’re looking for people like you to join our team.See details»
Alchemab Therapeutics 2025 Company Profile: Valuation, Funding ...
Alchemab Therapeutics was founded in 2019. Where is Alchemab Therapeutics headquartered? Alchemab Therapeutics is headquartered in London, United Kingdom. What is the size of …See details»
Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal
6 days ago Eli Lilly inked a licensing agreement with Alchemab Therapeutics, gaining access to the U.K. biotech’s early-stage therapy for amyotrophic lateral sclerosis.. Financial details of the …See details»
Alchemab Therapeutics – Undisclosed solid tumor target - lifespan
Alchemab specializes in antibody mining. First, they identify exceptionally immunologically resilient individuals. ... Lifespan Research Institute is a 501(c)(3) non-profit organization …See details»
Alchemab's new well-connected CEO will lead biotech on journey …
Jun 22, 2021 After overseeing the $2.5 billion acquisition of Ra Pharmaceuticals last year, Douglas Treco, Ph.D., will lead Alchemab Therapeutics in its quest to develop therapies for | …See details»